Monitoring for Metabolic Syndrome in Adults with Intellectual Disability on Atypical Antipsychotic Drugs

References

• Alberti, K.G., Zimmet, P. and Shaw, J (2006). Metabolic syndrome — a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Medicine, 23, 469–480.
   PubMed Web of Science ®Google Scholar
• Alberti, K.G. and Zimmet, P. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Medicine, 15:539–53.
   PubMed Web of Science ®Google Scholar
• Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C. and Infante M.C. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156: 1686–1696.
   Google Scholar
• American Diabetic Association. (2004). Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, 27, 596 —601.
   Web of Science ®Google Scholar
• Bhaumik, S., Watson. J.M., Smith. J.F.F., Nadkarni. S., Biswas. A., Gangadharan. S.K. A lithium register for adults with intellectual disabilities - Can it work? British Journal of Developmental Disabilities, 2007, 53(1), 37–45.
   Google Scholar
• BNF 55 (British National Formulary) March 2008. BMJ Group and Royal Pharmacological Society Publishing 2008.
   Google Scholar
• Branford, D. (1994). A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. Journal of Intellectual Disability Research, 38, 577–586.
   Web of Science ®Google Scholar
• Branford, D. (1996). A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. Journal of Intellectual Disability Research, 40, 358–368
   PubMed Web of Science ®Google Scholar
• Brylewslci, J. and Duggan, L. (2003). Antipsychotic medication for CB in PVVID. Cochrane database of systematic reviews (I: 3), 1–26
   Google Scholar
• Brown, S. (1997). Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry, 171, 502–508.
   PubMed Web of Science ®Google Scholar
• Brown, S., Birtwistle, J., Roe, L. and Thompson, C. (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29, 697–701.
   PubMed Web of Science ®Google Scholar
• Clarke, D.J., Kelley, S., Thinn, K. and Corbett, J.A. (1990). Psychotropic drugs in mental retardation: I. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. Journal of Mental Deficiency Research 34, 385 395.
   Google Scholar
• Corbett, J. (1979). Psychiatric morbidity and mental retardation. In Editor Corbett J., Psychiatric Illness and Mental Handicap, 11–23 London: Royal College of Psychiatrists, Gaskell Press.
   Google Scholar
• Deb, S. and Fraser, W. (1994). The use of psychotropic medication in people with learning disability: towards rational prescribing. Human Psychopharmacology, 9, 259–272.
   Web of Science ®Google Scholar
• Department of Health (2001). Valuing people: A New Strategy for Learning Disability for the 21st Century. TS0 (The Stationary Office).
   Google Scholar
• Disability Rights Commission (DRC) Report (2006). Equal Treatment: Closing the Gap. www.drc-gb.org/healthinvestigation
   Google Scholar
• The IDF worldwide consensus definition of the Metabolic Syndrome (2006). International Diabetes Federation. IDF Communications, Brussels, Belgium. www.idf.org/home/index.cfm?node= 1429
   Google Scholar
• Joint British Societies (2005). JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (supplement 5) 1–52.
   Google Scholar
• Khan, B.U. (1997). Brief report: Risperidone for severely disturbed behaviour and tardive dyskinesia in developmentally disabled adults. Journal of Autism Developmental Disorders, 27, 479–489.
   Web of Science ®Google Scholar
• Lawrence, D.M., Holman, C.D.J., Jablensky, A.V. and Hobbs M.S.T (2003). Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980–1998. British Journal of Psychiatry, 182, 31–36.
   PubMed Web of Science ®Google Scholar
• Leicestershire Partnership NHS Trust (2007). Guidance on the monitoring of metabolic parameters in patients with serious mental illness prescribed regular antipsychotics ( Version March 2007) //tinyurl.com/2anqlz
   Google Scholar
• Linaker, O.M. (1990). Frequency of and determinants for psychotropic drug use in an institution for the mentally retarded. British Journal of Psychiatry, 156, 525–530.
   PubMed Web of Science ®Google Scholar
• Lund, J. (1985). The prevalence of psychiatric morbidity in mentally retarded adults. Acta Psychiatrica Scandinavica, 72, 563–570.
   PubMed Web of Science ®Google Scholar
• McCreadie, R.G. (2003). Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. British Journal of Psychiatry, 183, 534–539.
   PubMed Web of Science ®Google Scholar
• McGrother, C.W., Hauck, A., Bhaumik, A., Thorp, C. and Taub, N. (1996). Community care for adults with learning disability and their carers: needs and outcomes from the Leicestershire register. Journal of Intellectual Disability Research 40, 183–190.
   PubMed Web of Science ®Google Scholar
• Mencap (2004). Treat Me Right. Mencap.
   Google Scholar
• Mencap (2007). Death by Indifference. Mencap.
   Google Scholar
• Mukherjee, S., Schnur, D. B. and Reddy, R. (1989). Family history of type 2 diabetes in schizophrenic patients. Lancet, 8636, 495.
   Google Scholar
• Newcomer, J.W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19, Supplement 1, 1–93.
   PubMedGoogle Scholar
• Osborn, D.P., Levy, G., Nazareth, I., Petersen, I., Islam, A. and King, M.B. (2007). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database. Archives of General Psychiatry. 64,242–249.
   PubMed Web of Science ®Google Scholar
• Phelan, M., Stradins, L. and Morrison, S. (2001). Physical health of people with severe mental illness. British Medical Journal. 322, 443–444.
   PubMed Web of Science ®Google Scholar
• Ryan, M.C.M., Collins, P. and Thakore, J.H. (2003). Impaired fasting glucose and elevation of cortisol in drug-naïve first-episode schizophrenia. American Journal of Psychiatry, 160, 284–289.
   PubMed Web of Science ®Google Scholar
• Ryan, M.C.M., Flanagan, S. and Kinsella, U. (2004). Atypical antipsychotics and visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sciences, 74, 1999–2008.
   PubMed Web of Science ®Google Scholar
• Thakore, J. H. (ed.) (2001). Physical Consequences of Depression. Cambridge, Wrightson.
   Google Scholar
• Thakore, J.H., Vlahoos, J. and Martin, A. (2002). Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. International Journal of Obesity Related Metabolic Disorders, 26, 137–141.
   PubMed Web of Science ®Google Scholar
• Tin, N.N., Devapriam, J., Raju, L.B. and Bhaumik, S. (2008). Use of atypical antipsychotics in people with intellectual disability - is it atypical? The British Journal of Developmental Disabilities, 54, 101–111.
   Web of Science ®Google Scholar
• Tyrer, P., Oliver-Africano, P.C., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., Murphy, D., Hare, M., Meade, M., Reece, B., Kramo, K., Bhaumik, S., Harley, D., Regan, A., Thomas, D., Rao, B., North, B., Eliahoo, J., Karatela, S., Soni, A. and Crawford, M. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disabilities: a randomised controlled trial. Lancet, 371, 57–63
   PubMed Web of Science ®Google Scholar
• Welsh Office (1996). Welsh Health Survey 1995. Welsh Office.
   Google Scholar
• Zhang, Z.J., Yao, Z.J. and Li, W. (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. British Journal of Psychiatry, 184, 58–62.
   PubMed Web of Science ®Google Scholar